Oyster Point Pharma initiated at overweight with $26 price target at JP Morgan
 (neutral)The output is 1 (neutral) because the tweet does not express an emotional sentiment about the market trend. It simply states facts about Oyster Point Pharma's stock rating and corresponding price target established by JP Morgan.